Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online March 17, 2022.
Article Versions
- You are currently viewing a previous version of this article (March 17, 2022 - 12:57).
- View the most recent version of this article
Copyright & Usage
Copyright © 2022 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Author Information
- Louise M Emmett1,
- Nathan Papa2,
- James Buteau3,
- Bao Ho4,
- Victor Liu5,
- Matthew Roberts6,
- James Thompson7,
- Daniel Moon8,
- Gemma Sheehan-Dare9,
- Omar Alghazo8,
- Shikha Agrawal10,
- Declan G. Murphy11,
- Phillip Stricker12,
- Thomas A. Hope13 and
- Michael Hofman14
- 1 Department of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney, Australia;
- 2 School of Public Health and Preventive Medicine, Monash University, Australia;
- 3 Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer, Melbourne;
- 4 Department of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney, Australia.;
- 5 Department of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney, Australia;
- 6 Department of Urology, Royal Brisbane and Women's Hospital, Brisbane;
- 7 Department of Urology, St. George Hospital, Australia;
- 8 Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
- 9 Gosford Hospital;
- 10 Garvan Institute of Medical Research;
- 11 Peter MacCallum Cancer Centre;
- 12 St. Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia;
- 13 University of California, San Francisco;
- 14 Peter MacCallum Cancer Centre, Melbourne, Australia
- For correspondence or reprints contact: Louise M. Emmett, Department of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney, 390 Victoria Street, Darlinghurst, NSW 2010, Australia. E-mail: emmetthruby@gmail.com
Statistics from Altmetric.com
Cited By...
Article usage
In this issue
Jump to section
Related Articles
Cited By...
- Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [68Ga]Ga-PSMA-11 PET/CT in the proPSMA Study
- The PRIMARY Score: Present and Future
- Diagnostic Performance of [18F]AlF-Thretide PET/CT in Patients with Newly Diagnosed Prostate Cancer Using Histopathology as Reference Standard
- The Value of 68Ga-PSMA PET/MRI for Classifying Patients with PI-RADS 3 Lesions on Multiparametric MRI: A Prospective Single-Center Study
- Diagnostic Performance of 68Ga-PSMA-11 PET/CT Versus Multiparametric MRI for Detection of Intraprostatic Radiorecurrent Prostate Cancer
- Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database
- A Prostate-Specific Membrane Antigen PET-Based Approach for Improved Diagnosis of Prostate Cancer in Gleason Grade Group 1: A Multicenter Retrospective Study
- 68Ga-PSMA PET/CT and Prostate Cancer Diagnosis: Which SUVmax Value?